DIABETES
In emerging markets, "introducing blockbuster insulin organizations" may not always bе аn effective strategy. For example, in some target markets, the islamic population represents а significant number of people, and religion dominates public opinion. In this regard, availability of so-called "halal" insulin (which means "religiously" pure preparation of non-animal or bacterial origin) is а very important factor.
So far, the UAE and other countries in the Middle East had to import most of their diabetes medicaments. Thus, governments in these regions are interested in attracting drugs from foreign manufacturers who recognize the importance of local traditions and cultures. Gorbiopharm, in turn, is planning to manufacture human insulin from genetically engineered plants.
Number of people with diabetes worldwide and by IDF region 2021-2045 (20-79 years)
World
- 2024 (588.7 Million)
- 2050 (852.5 Million)
- +45% Increse
Africa
- 2024 (24.6 Million)
- 2050 (59.5 Million)
- +142% Increse
Europe (EUR)
- 2024 (65.6 Million)
- 2050 (72.4 Million)
- +10% Increse
Middle-East and North Africa (MENA)
- 2024 (84.7 Million)
- 2050 (162.6 Million)
- +92% Increse
North America and Caribbean (NAC)
- 2024 (56.2 Million)
- 2050 (68.1 Million)
- +21% Increse
South and Central America (SACA)
- 2024 (35.4 Million)
- 2050 (51.5 Million)
- +45% Increse
South-East Asia (SEA)
- 2024 (106.9 Million)
- 2050 (184.5 Million)
- +73% Increse
Western Pacific (WP)
- 2024 (215.4 Million)
- 2050 (253.8 Million)
- +18% Increse
Million adults are living with diabetes. This number is predicted to rise to 853 million by 2050
0
Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds.
0
Diabetes caused at least USD 1 trillion dollars in health expenditure – a 338% increase over the last 17 years.
0
Highlights
°
589 million adults (20-79 years) are living with diabetes worldwide – 1 in 9.
°
The total number of adults with diabetes is predicted to rise to 853 million by 2050 - 1 in 8.
°
4 in 5 adults with diabetes (81%) live in low and middle-income countries.
°
Diabetes caused 3.4 million deaths in 2024 – 1 every 6 seconds.
°
An estimated 43% of adults living with diabetes (252 million people) are undiagnosed. Almost 90% live in low and middle-income countries.
°
Diabetes was responsible for an estimated USD 1.015 trillion in global health expenditure in 2024. This represents a 338% increase over the past 17 years.
°
635 million adults worldwide (1 in 8) have impaired glucose tolerance and 488 million have impaired fasting glucose (1 in 11) placing them at high risk of type 2 diabetes.
°
1 in 5 live births are affected by hyperglycaemia in pregnancy.
BUSINESS STRATEGY
While the epidemiology of diabetes and the unmet need to increase supply of insulin mean that there are multi-Ьillion-dollar opportunities, success of entering the mature insulin market is still highly controversial. Today, biosimilar producing companies face signif1cant regulatory, commercial, and competitive challenges to enter the market. Given these obstacles, complexity and cost of producing insulin, it is unlikely that numerous biosimilars will appear оn the insulin market in the near future.
Gorbiopharm is going to focus mainly оп smaller markets. Today, the most of insulin biosimilar companies are targeting mature markets at the expense of emerging markets, based оn assumptions about where the greatest return оп investment саn bе achieved.
Gorbiopharm believes that the most realistic and viable market entry strategy is to succeed in emerging markets through adaptation to local conditions, rather than through success in а mature market. In these markets, insulin remains unaffordable. And according to studies, these markets will account for almost 80% of the global diabetes market Ьу 2030. Thus, the dynamics of products introduced to emerging markets for the first time is assumed to Ье more flexible than in developed markets.
CREATION OF A HIGH-TECH BIOPHARMACEUTICAL COMPLEX FOR THE PRODUCTION OF GENETICALLY ENGINEERED MEDICINES
“Improving public health is our top priority.”
The President of the Republic of Uzbekistan
Shavkat Miromonovich Mirziyoyev
DIABETES IS A GLOBAL EMERGENCY
Diabetes is one of the biggest global health emergencies of the 21st century. And it reached pandemic proportions. The International Diabetes Federation (IDF) estimates that in 2021, 536.6 million people worldwide had diabetes, and the disease accounted for more than $966 billion in global healthcare spending. The IDF estimates that in 2045 there will be 783.2 million diabetic patients worldwide and healthcare costs of US$1.054 billion.
According to the same estimates, diabetes is the third leading cause of death after cardiovascular diseases and cancer. In 2021 only, about 6.7 million deaths worldwide were directly attributable to diabetes. This is equivalent to one death every eight seconds and is estimated to be associated with 12.2% of global deaths from all causes among the world’s population. More than 80.6% of deaths occur in middle- and low-income countries.
Given significant therapeutic value of insulin, all manufacturers still lack production capacity to meet the demand and ensure adequate and stable supply. As estimated, 60-65 million people do not have access to this life-saving medicine, which is an essential and urgent need. Universal availability of insulin for people with diabetes is seen as a basic human right, but almost a century after its discovery, insulin remains largely unavailable, expensive, or both. To date, the coverage of the need for insulin in the world is about 18-20%.